Abstract:Long‐term outcomes of patients undergoing percutaneous coronary intervention with drug‐eluting stents for acute coronary syndrome (ACS) or chronic coronary syndrome (CCS) were investigated. Compared with CCS patients, ACS patients have an increased risk of all‐cause death and repeat revascularization of remote vessels up to 1‐year follow‐up, with no significant differences thereafter. ACS patients have a consistently higher risk of MI and definite ST up to 10‐year follow‐up. Background Investigations of very long‐term outcomes after percutaneous coronary intervention (PCI) with drug‐eluting stents (DES) according to clinical presentation are scarce. Here, we investigated the 10‐year clinical outcomes of patients undergoing DES‐PCI according to clinical presentation. Methods Patient‐level data from five randomized trials with 10‐year follow‐up after DES‐PCI were pooled. Patients were dichotomized into acute coronary syndrome (ACS) or chronic coronary syndrome (CCS) groups as per clinical presentation. The primary outcome was all‐cause death. Secondary outcomes were cardiovascular death, myocardial infarction (MI), definite stent thrombosis (ST) and repeat revascularization involving the target lesion (TLR), target vessel (TVR) or non‐target vessel (nTVR). Results Of the 9700 patients included in this analysis, 4557 presented with ACS and 5143 with CCS. Compared with CCS patients, ACS patients had a higher risk of all‐cause death and nTVR in the first year, but comparable risk thereafter. In addition, ACS patients had a higher risk of MI [adjusted hazard ratio 1.21, 95% confidence interval (1.04–1.41)] and definite ST [adjusted hazard ratio 1.48, 95% confidence interval (1.14–1.92)], while the risk of TLR and TVR was not significantly different up to 10‐year follow‐up. Conclusions Compared to CCS patients, ACS patients treated with PCI and DES implantation have an increased risk of all‐cause death and repeat revascularization of remote vessels up to 1 year, with no significant differences thereafter and up to 10‐year follow‐up. ACS patients have a consistently higher risk of MI and definite ST. Whether these differences persist with current antithrombotic and secondary prevention therapies requires further investigation.

Clinical Characteristics of Early and Late Drug-Eluting Stent In-Stent Restenosis and Mid-Term Prognosis after Repeated Percutaneous Coronary Intervention.

[Long-Term Outcomes and Risk Factors of Ostial/shaft Lesions in Unprotected Left Main Coronary Artery after Percutaneous Coronary Intervention].

Clinical Outcomes and Risk Factors of Coronary Artery Aneurysms after Successful Percutaneous Coronary Intervention and Drug-Eluting Stent Implantation for Chronic Total Occlusions

Drug-eluting Balloons Versus Drug-Eluting Stents for the Management of In-Stent Restenosis: A Meta-Analysis of Randomized and Observational Studies

Long-Term Effects of Drug-Eluting Stents Versus Bare Metal Stents on Patients with Acute St-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes of 3-Year Clinical Follow-Up

Long-term Prognosis of Drug Eluting Stents Implantation in Elderly Patients with Unprotected Left Main Coronary Artery Disease

Association Between Periprocedural Myocardial Injury and Neointimal Characteristics in Patients with In-Stent Restenosis: an Optical Coherence Tomography Study.

Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis.

Effect of Drug Eluting stent Implantation in the Treatment of Coronary Artery In-stent Restenosis in a Longterm Clinical Follow-up

Factors Influencing Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Heart Disease: A Clinical Trial Based on 1-Year Follow-Up

Mid-term treatment results of drug-eluting stent implantation for patients with multivessel chronic total coronary occlusion lesions

Clinical Outcome after Management of Unprotected Left Main In-Stent Restenosis after Bare Metal or Drug-Eluting Stents

A More Than 2-Year Follow-Up of Incomplete Apposition after Drug-Eluting Stent Implantation

Ten‐year clinical outcomes after drug‐eluting stents implantation according to clinical presentation—Insights from the DECADE cooperation

Long-term clinical outcomes of successful revascularization with drug-eluting stents for chronic total occlusions: A systematic review and meta-analysis.

Investigation Into the Risk Factors Related to In-stent Restenosis in Elderly Patients With Coronary Heart Disease and Type 2 Diabetes Within 2 Years After the First Drug-Eluting Stent Implantation

Incidence and risk factors of in-stent restenosis after percutaneous coronary intervention in patients from southern China

Same or Different Drug-Eluting Stent Re-Implantation for Drug-Eluting Stent Restenosis: An Assessment Including Second-Generation Drug-Eluting Stents

In-Stent Restenosis: Achilles’ Heel of Post-PCI Era

Drug-coated balloon angioplasty versus drug-eluting stent implantation in ACS patients with different angiographic patterns of in-stent restenosis

Non-target lesion progression: Unveiling critical predictors and outcomes in patients with in-stent restenosis